On June 22, Innovent Biologics fell 3.68% in regular trading, trading at 72.5 HKD/share, with turnover of approximately 80.58 million HKD.

The decline was primarily driven by broad sector weakness across the biotechnology industry. Within the sector, AKESO fell 5.83%, SKB Bio fell 6.83%, Remegen fell 4.45%, 3SBio fell 4.5%, and BeiGene fell 3.3%, indicating systematic selling pressure rather than company-specific catalysts. Notably, the stock had previously rebounded to 78.75 HKD on June 15 following PCSK9 inhibitor approval and ADA conference data, and gained further on June 18 amid EULAR conference catalysts. The current pullback erases recent gains as broader market rotation toward AI and technology sectors continues to divert capital away from healthcare and biotech names. Separately, the company announced on the same day that its IBI3003 triple-specific antibody for multiple myeloma completed first patient dosing in a Phase III trial, though the positive pipeline development has not offset prevailing sector headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)